NASDAQ · GSK
Healthcare · Drug Manufacturers - General
$46.50
Down-$0.04 (-0.09%)
Updated Oct 10, 2026, 8:17 PM
SID Score
5.6/10
Composite research score
Smart Money
56/100
Neutral
Price performance · GSK
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 9, 2026
GSK closed at $46.50 after 21 trading sessions, down 3.39% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 9, 2026 | $46.61 | $46.82 | $46.265 | $46.50 | 8.54M |
| Oct 8, 2026 | $46.40 | $46.70 | $45.825 | $46.54 | 7.73M |
| Oct 7, 2026 | $46.92 | $47.405 | $46.69 | $47.02 | 5.85M |
| Oct 6, 2026 | $46.96 | $47.01 | $46.175 | $46.60 | 6.81M |
| Oct 5, 2026 | $46.73 | $46.885 | $46.33 | $46.55 | 3.48M |
| Oct 2, 2026 | $47.08 | $47.16 | $46.84 | $47.03 | 5.39M |
| Oct 1, 2026 | $48.16 | $48.23 | $47.13 | $47.18 | 7.9M |
| Sep 30, 2026 | $48.925 | $49.05 | $48.17 | $48.17 | 5.85M |
| Sep 29, 2026 | $49.405 | $49.82 | $48.9623 | $49.35 | 2.89M |
| Sep 28, 2026 | $49.17 | $49.80 | $48.98 | $49.70 | 3.59M |
| Sep 25, 2026 | $49.49 | $49.495 | $49.00 | $49.24 | 3.32M |
| Sep 24, 2026 | $49.59 | $50.1395 | $49.565 | $49.65 | 2.84M |
| Sep 23, 2026 | $50.18 | $50.74 | $49.67 | $49.71 | 3.04M |
| Sep 22, 2026 | $50.69 | $50.99 | $50.22 | $50.72 | 4.3M |
| Sep 21, 2026 | $50.75 | $51.32 | $50.46 | $51.08 | 2.87M |
| Sep 18, 2026 | $50.20 | $50.33 | $49.50 | $50.22 | 4.71M |
| Sep 17, 2026 | $50.72 | $51.075 | $50.62 | $51.06 | 3.08M |
| Sep 16, 2026 | $50.19 | $50.71 | $50.055 | $50.29 | 2.84M |
| Sep 15, 2026 | $49.69 | $50.155 | $49.63 | $50.01 | 2.74M |
| Sep 14, 2026 | $50.29 | $50.30 | $49.61 | $50.05 | 3M |
| Sep 11, 2026 | $48.70 | $48.80 | $47.85 | $48.13 | 2.28M |
The latest Smart Investors Daily articles mentioning GSK.
Company
Market Activity
Research & News
GSK research
Company profile and research snapshot.
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jun 8, 2026 | Deutsche | Hold | — |
| May 28, 2026 | Jefferies | Buy | — |
| May 27, 2026 | Deutsche | Hold | — |
| May 6, 2026 | Deutsche | Hold | — |
| May 6, 2026 | Citigroup | Neutral | — |
No generated briefing is available yet.
Benzinga · Oct 9, 2026
- Reuters
Yahoo · Oct 8, 2026
GSK plc (LSE/NYSE: GSK) today announced a partnership with award-winning actress, producer and philanthropist Viola Davis to launch "Shingles, actually", a new educational campaign designed to spark conversations about the realities of aging, including the risk of shingles for adults 50 years and older. As part of the "Shingles, actually" campaign, Viola discusses her own experience with shingles for the first time, including its impact on her work and personal life, while encouraging the 50+ co
Yahoo · Oct 8, 2026
GSK (LSE:GSK) has entered a collaboration with Wave Life Sciences to advance a GalNAc-siRNA hepatology candidate into its development pipeline. The partnership with Wave Life Sciences focuses on RNA-based therapies targeting liver diseases using GalNAc-siRNA technology. GSK expanded its tuberculosis research with AN2 Therapeutics, supported by new funding from the Bill & Melinda Gates Foundation for boron-based drug discovery. The Wave Life Sciences hepatology move and fresh Gates-backed TB...
Yahoo · Oct 7, 2026
GSK has pulled off a 52.5% share price gain over the past 5 years, yet with recent weakness on the screen, the live question for investors is whether that track record lines up with what the company is actually earning today. The issue is not just where the stock has come from, but whether GSK's current earnings power still supports the price you see now. That 52.5% rise over 5 years puts real weight on the question of whether GSK's current earnings profile can carry the valuation further or...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning GSK.
